Thanks for the cure, CRISPR. Now companies want a pill to treat sickle-cell disease instead. The company that just got approval to sell the first gene-editing treatment in history, for sickle-cell ...
At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play. On ...
The Anna Head Alumnae Hall at UC Berkeley was packed with more than 200 attendees Wednesday evening as Feng Zhang, professor of biomedical engineering at the Massachusetts Institute of Technology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback